Your browser doesn't support javascript.
loading
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
Gold, Ralf; Piani-Meier, Daniela; Kappos, Ludwig; Bar-Or, Amit; Vermersch, Patrick; Giovannoni, Gavin; Fox, Robert J; Arnold, Douglas L; Benedict, Ralph H B; Penner, Iris-Katharina; Rouyrre, Nicolas; Kilaru, Ajay; Karlsson, Göril; Ritter, Shannon; Dahlke, Frank; Hach, Thomas; Cree, Bruce A C.
Afiliação
  • Gold R; Department of Neurology, St. Josef Hospital and Ruhr University of Bochum, Bochum, Germany. ralf.gold@ruhr-uni-bochum.de.
  • Piani-Meier D; Novartis Pharma AG, Basel, Switzerland.
  • Kappos L; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and Multiple Sclerosis Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital, University of Basel, Basel, Switzerland.
  • Bar-Or A; Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Vermersch P; University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France.
  • Giovannoni G; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Fox RJ; Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Arnold DL; NeuroRx Research, Montreal, QC, Canada and Montreal Neurological Institute, McGill University, Montreal, QC, Canada.
  • Benedict RHB; Department of Neurology, University at Buffalo, Buffalo, NY, USA.
  • Penner IK; Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Rouyrre N; Novartis Pharma AG, Basel, Switzerland.
  • Kilaru A; Novartis Pharma AG, Basel, Switzerland.
  • Karlsson G; Novartis Pharma AG, Basel, Switzerland.
  • Ritter S; Novartis Pharma AG, Basel, Switzerland.
  • Dahlke F; Novartis Pharma AG, Basel, Switzerland.
  • Hach T; Novartis Pharma AG, Basel, Switzerland.
  • Cree BAC; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
J Neurol ; 269(9): 5093-5104, 2022 Sep.
Article em En | MEDLINE | ID: mdl-35639197
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azetidinas / Esclerose Múltipla Crônica Progressiva / Esclerose Múltipla Recidivante-Remitente / Esclerose Múltipla Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: J Neurol Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Azetidinas / Esclerose Múltipla Crônica Progressiva / Esclerose Múltipla Recidivante-Remitente / Esclerose Múltipla Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: J Neurol Ano de publicação: 2022 Tipo de documento: Article